All Stories

  1. Data from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  2. Supplementary Figure S1 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  3. Supplementary Figure S2 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  4. Supplementary Figure S3 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  5. Supplementary Figure S4 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  6. Supplementary Figure S5 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  7. Supplementary Figure S6 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  8. Supplementary Figure S7 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  9. Supplementary Table 1 from DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • December 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  10. DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells

    Article • Molecular Cancer Research, September 2025, American Association for Cancer Research (AACR)

    Dr Julien LESAGE

  11. ZO-1 Intracellular Localization Organizes Immune Response in Non-Small Cell Lung Cancer

    Article • Frontiers in Cell and Developmental Biology, December 2021, Frontiers

    Dr VALERIAN DORMOY, Dr Julien LESAGE

  12. EMT and inflammation: inseparable actors of cancer progression

    Article • Molecular Oncology, June 2017, Wiley

    Dr Julien LESAGE

  13. ZO-1 is proangiogenic

    Article • The FASEB Journal, January 2017, Federation of American Societies For Experimental Biology (FASEB)

    Dr Julien LESAGE, Walter Hunziker

  14. Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment

    Article • The Journal of Pathology, May 2015, Wiley

    Dr Julien LESAGE

  15. Cystic fibrosis airway epithelium remodelling: involvement of inflammation

    Article • The Journal of Pathology, December 2014, Wiley

    Dr Julien LESAGE

  16. Implication des Zonula Occludens dans la progression métastatique des cancers broncho-pulmonaires

    Article • Agence Bibliographique de l'Enseignement Supérieur

    Dr Julien LESAGE